Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Purchases 21,000 Shares of Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar acquired 21,000 shares of Anixa Biosciences stock in a transaction on Friday, June 12th. The shares were bought at an average price of $2.50 per share, with a total value of $52,500.00. Following the completion of the transaction, the chief executive officer directly owned 630,812 shares of the company’s stock, valued at $1,577,030. This trade represents a 3.44% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Anixa Biosciences Stock Performance

NASDAQ:ANIX opened at $2.61 on Wednesday. The company has a fifty day moving average of $2.78 and a two-hundred day moving average of $3.06. The stock has a market capitalization of $88.79 million, a PE ratio of -8.42 and a beta of 0.59. Anixa Biosciences Inc has a fifty-two week low of $2.32 and a fifty-two week high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Wednesday, June 10th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. Research analysts forecast that Anixa Biosciences Inc will post -0.31 earnings per share for the current year.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds have recently modified their holdings of the business. Segall Bryant & Hamill LLC acquired a new stake in shares of Anixa Biosciences in the first quarter valued at about $45,000. Renaissance Technologies LLC raised its position in shares of Anixa Biosciences by 13.6% in the first quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock valued at $158,000 after buying an additional 7,300 shares during the last quarter. Kestra Advisory Services LLC raised its position in shares of Anixa Biosciences by 96.2% in the first quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock valued at $132,000 after buying an additional 25,000 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences in the fourth quarter valued at about $161,000. Finally, Millennium Management LLC acquired a new stake in shares of Anixa Biosciences in the fourth quarter valued at about $38,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ANIX shares. Citigroup restated a “buy” rating on shares of Anixa Biosciences in a research report on Friday. D. Boral Capital reiterated a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday, April 8th. HC Wainwright reiterated a “buy” rating on shares of Anixa Biosciences in a research report on Friday. Finally, Wall Street Zen cut shares of Anixa Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.50.

About Anixa Biosciences

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.